हमें इंस्टाग्राम पर फॉलो करें
एक बाहरी कंपनी से अधिक।

Cost and quality-adjusted life years of alpha-gal IgE screening vs. not screening in asymptomatic patients suggest that screening is not cost-effective.
Watch videoCost and quality-adjusted life years of alpha-gal IgE screening vs. not screening in asymptomatic patients suggest that screening is not cost-effective to prevent fatal anaphylaxis, according to study findings.
These data were published in The Journal of Allergy and Clinical Immunology: In Practice.
Continue reading to learn more about screening for Alpha-Gal, written by Isabella Hornick.


Cost and quality-adjusted life years of alpha-gal IgE screening vs. not screening in asymptomatic patients suggest that screening is not cost-effective to prevent fatal anaphylaxis, according to study findings.
These data were published in The Journal of Allergy and Clinical Immunology: In Practice.
Continue reading to learn more about screening for Alpha-Gal, written by Isabella Hornick.


Cost and quality-adjusted life years of alpha-gal IgE screening vs. not screening in asymptomatic patients suggest that screening is not cost-effective to prevent fatal anaphylaxis, according to study findings.
These data were published in The Journal of Allergy and Clinical Immunology: In Practice.
Continue reading to learn more about screening for Alpha-Gal, written by Isabella Hornick.
एक बाहरी कंपनी से अधिक।